Dimerix
Business Services · Australia · 11-50 Employees
View Company Info for Free
Overview
Headquarters
425 Smith St, Fitzroy, Victoria, 3065, A...Phone Number
+61 1300813321Website
www.dimerix.comRevenue
<$5 MillionStock Symbol
DXBIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Dimerix
Founded in 2004, based out of Australia, Dimerix (ASX: DXB) is a clinical-stage biopharmaceutical company developing innovative new therapies in areas with unmet medical needs for global markets. Dimerix is currently developing its proprietary product DMX-200 for both Diabetic Kidney Disease and Focal Segmental Glomerulosclerosis (FSGS). DMX-200 was identified using Dimerix' proprietary assay, Receptor Heteromer Investigation Technology (Receptor-HIT), which is a scalable and globally applicable technology platform enabling the understanding of receptor interactions to rapidly screen and identify new drug opportunities. Receptor-HIT is licensed non-exclusively to Excellerate Bioscience, a UK-based pharmacological assay service provider with a worldwide reputation for excellence in the field of molecular and cellular pharmacology.Explore more
Dimerix Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Dimerix your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Dimerix recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Dimerix has recently received funding, and reach out quickly before it becomes old news!
Click to see if Dimerix had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Dimerix
Funding: Get notified immidiatlly once Dimerix has new funding data
Dimerix, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Dimerix launches new products
Check out if Dimerix is spiking on competitors!
Recommended Actions
Find VP level buyers at Dimerix
Find 2 more new buyers
Compare Similar Companies to Dimerix
Compare insights from companies similar to Dimerix, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Dimerix is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Dimerix is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Dimerix.
Dimerix financials insights
Gather financial insights about Dimerix, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Share Placement
$20M
2023
Other Financing Round
$8.7M
Dimerix Tech Stack
A closer look at the technologies used by Dimerix
Most Recent Scoops
Partnership
Project
Partnership, Product Management, Business Development, Intellectual Property, Legal Affairs, Medical Research, Pharmaceuticals
Project
expects to achieve several milestones in Q3 and Q4 2025, including outcomes from the PFIZER opportunity, FDA feedback, a blinded interim analysis, full recruitment for the DMX-200 clinical trial, and the introduction of additional pipeline opportunities.
Product Development, Pharmaceuticals, Clinical Operations
Project
Dimerix is exploring accelerated approval pathways for DMX-200 in focal segmental glomerular sclerosis (FSGS) across multiple territories, including Europe and Japan, while continuing to collect both proteinuria and eGFR data for two years to meet global regulatory requirements.
Governmental Affairs & Regulation, Pharmaceuticals, Clinical Operations, Regulations
Project
Dimerix is participating in an FDA-led working group focused on determining appropriate endpoints for focal segmental glomerular sclerosis (FSGS) clinical trials. The group has confirmed eGFR as a validated endpoint and recognized proteinuria as a potential earlier indicator of efficacy.
Governmental Affairs & Regulation, Pharmaceuticals, Clinical Operations, Regulations
Project
Medical Research, Pharmaceuticals, Clinical Operations
Dimerix News & Media
Mission Therapeutics strikes deal worth up to $292 million for Dimerix Ltd to develop Acute Kidney Injury asset MTX652, sharpens focus on its CNS pipeline
Mission Therapeutics strikes deal worth up to $292 million for Dimerix Ltd to develop Acute Kidney Injury asset MTX652, sharpens focus on its CNS pipeline.DIMERIX EXPANDS PIPELINE WITH ACQUISITION OF PHASE 2 READY ASSET FOR ACUTE KIDNEY INJURY
Highlights Dimerix acquires Phase 2-ready asset, DMX-652 - with potential for rapid advancement into a Phase 2 clinical study under an open US Investigational New Drug (IND) application, with initial focus on acute kidney injury (AKI) DMX-652 offers potential to address a significant unmet need in AKI - with a global market opportunity estimated to be US$3.5 billion in 2026,[1] and no currently approved therapies for the disease which is associated with rapid decline inEverest Medicines Enters into Exclusive Licensing Agreement with Dimerix for DMX-200 in Greater China, South Korea and Southeast Asia
HONG KONG, Jun 16, 2026 - (ACN Newswire) - Everest Medicines (HKEX 1952.HK)announced that it has entered into an exclusive licensing agreement with Australia Dimerix Limited (“Dimerix”), for the development and commercialization of DMX-200 in Greater China (Chinese mainland, Hong Kong SAR, Macao SAR and Taiwan region), South Korea and certain Southeast Asian countries (Singapore, Malaysia, Thailand, Indonesia, Vietnam and Philippines). This collaboration will further strengthen Everest’s nephrolDIMERIX EXCLUSIVELY LICENSES DMX-200 IN GREATER CHINA, SOUTH KOREA AND SOUTHEAST ASIA TO EVEREST MEDICINES
Everest Medicines licenses exclusive rights to commercialise DMX-200 for the treatment of Focal Segmental Glomerulosclerosis (FSGS) in Greater China, South Korea and Southeast Asia 500,000-1 million people are estimated to be living with FSGS in the territories[1] Dimerix eligible to receive upfront and potential success-based milestone payments of up to ~AU$481[2] million, plus royalties US$10 million (~AU$14.1 million2) upfront payment Up to US$330 million (~AU$467 million2) in potential miles
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Top companies in United Kingdom by revenue
Frequently Asked Questions Regarding Dimerix
Sign Up For FreeTo access detailed company insights
Founded in 2004, based out of Australia, Dimerix (ASX: DXB) is a clinical-stage biopharmaceutical company developing innovative new therapies in areas with unmet medical needs for global markets. Dimerix is currently developing its proprietary product DMX-200 for both Diabetic Kidney Disease and Focal Segmental Glomerulosclerosis (FSGS). DMX-200 wa... Read More
